Attached files
| file | filename |
|---|---|
| 10-K - FORM 10-K DECEMBER 31, 2009 - PROGENICS PHARMACEUTICALS INC | form10_k12312009.htm |
| EX-32.2 - EXHIBIT 32.2 CERTIFICATION - PROGENICS PHARMACEUTICALS INC | ex32_212312009.htm |
| EX-23.1 - EXHIBIT 23.1 CONSENT OF PRICEWATERHOUSECOOPERS - PROGENICS PHARMACEUTICALS INC | ex23_112312009.htm |
| EX-31.1 - EXHIBIT 31.1 CERTIFICATION - PROGENICS PHARMACEUTICALS INC | ex31_112312009.htm |
| EX-31.2 - EXHIBIT 31.2 CERTIFICATION - PROGENICS PHARMACEUTICALS INC | ex31_212312009.htm |
| EX-10.33 - EXHIBIT 10.33 TERMINATION AND TRANSITION AGREEMENT - PROGENICS PHARMACEUTICALS INC | ex10_3312312009.htm |
Exhibit
32.1
CERTIFICATION
PURSUANT
TO
18 U.S.C. SECTION 1350,
AS
ADOPTED PURSUANT TO
SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002
The
undersigned Chief Executive Officer and Chief Science Officer of Progenics
Pharmaceuticals, Inc. (the “Company”) does hereby certify as
follows:
This
annual report on Form 10-K of the Company for the period ended December 31,
2009 and filed with the Securities and Exchange Commission on the date hereof
(the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of
the Securities Exchange Act of 1934 and the information contained in the Report
fairly presents, in all material respects, the financial condition and results
of operations of the Company.
|
/s/
Paul J. Maddon
|
|
|
Date:
March 15, 2010
|
Paul
J. Maddon, M.D., Ph.D.
Chief
Executive Officer and Chief
Science
Officer (Principal Executive
Officer)
|
A signed
original of this written statement required by Section 906, or other document
authenticating, acknowledging, or otherwise adopting the signature that appears
in typed form within the electronic version of this written statement required
by Section 906, has been provided to Progenics Pharmaceuticals, Inc. and
will be retained by Progenics Pharmaceuticals, Inc. and furnished to the
Securities and Exchange Commission or its staff upon request.